ISSN 1662-4009 (online)

ey0015.3-7 | Congenital hypothyroidism | ESPEYB15

3.7 Mean high-dose L-thyroxine treatment is efficient and safe to achieve a normal IQ in young adult patients with congenital hypothyroidism

PE Aleksander , M Bruckner-Spieler , AM Stoehr , E Lankes , P Kuhnen , D Schnabel , A Ernert , W Stablein , ME Craig , O Blankenstein , A Gruters , H Krude

To read the full abstract: J Clin Endocrinol Metab 2018;103:1459-1469The ESPE guidelines on CH recommend an initial LT4 dose of 10-15 microgram/kg per day1. Infants with severe CH, defined by a very low pretreatment TT4 or FT4 concentration, should be treated with the highest initial dose. However, little is known about long-term effects on developmental and...

ey0015.3-17 | Reviews | ESPEYB15

3.17 Diagnostic utility of molecular and imaging biomarkers in cytological indeterminate thyroid nodules

EJ de Koster , LF de Geus-Oei , OM Dekkers , I van Engen-van Grunsven , J Hamming , EPM Corssmit , H Morreau , A Schepers , J Smit , WJG Oyen , D Vriens

To read the full abstract: Endocr Rev 2018;39:154-191This extensive paper reviews current state of knowledge concerning possible diagnostic accuracy of all available biomarkers used for molecular diagnostics and in nuclear medicine for investigation of thyroid nodules of indeterminate cytology....

ey0015.4-6 | New therapeutic options | ESPEYB15

4.6 Final adult height in long-term growth hormone-treated achondroplasia patients

D Harada , N Namba , Y Hanioka , K Ueyama , N Sakamoto , Y Nakano , M Izui , Y Nagamatsu , H Kashiwagi , M Yamamuro , Y Ishiura , A Ogitani , Y Seino

To read the full abstract: Eur J Pediatr 2017; 176:873-879Achondroplasia (ACH) is the most common genetic form of disproportionate short stature, occurring in 1:15,000 –1:40,000 live births [28]. Most patients have a gain of function mutation in the transmembrane domain of the fibroblast growth factor receptor 3 (FGFR3), leading to prolonged intracellular MAPK signalin...

ey0015.5-3 | New genes and gene mutations | ESPEYB15

5.3 CYP3A4 mutation causes vitamin D-dependent rickets type 3

JD Roizen , D Li , L O'Lear , MK Javaid , NJ Shaw , PR Ebeling , HH Nguyen , CP Rodda , KE Thummel , TD Thacher , H Hakonarson , MA Levine

To read the full abstract: J Clin Invest 2018;128:1913-1918Two rare genetic forms of vitamin D–dependent rickets exist: VDDR-1 caused by mutations in the genes encoding either the renal 1-α hydroxylase (CYP27B1: VDDR-1A) or the hepatic 25-hydroxylase (CYP2R1: VDDR-1B) and VDDR-2 caused by mutations in the vitamin D receptor signalling due to mutations in the gene encoding the ...

ey0015.11-8 | New Developments in Monogenic Obesity | ESPEYB15

11.8 Early-onset obesity: unrecognized first evidence for GNAS mutations and methylation changes

A Grüters-Kieslich , M Reyes , A Sharma , C Demirci , TJ DeClue , E Lankes , D Tiosano , D Schnabel , H Jüppner

To read the full abstract: J Clin Endocrinol Metab 2017; 102 (8): 2670-2677These case reports lead to an important conclusion which changes our diagnostic work-up of early-onset childhood obesity. The authors shows that thorough work-up of clinical cohorts, combined with genetic and epigenetic analyses, can define new characteristic features of known disorders. PHP1A, and surprisingly also PHP1B,...

ey0020.1-3 | Antenatal and Perinatal Thyroidology | ESPEYB20

1.3. Incidence of and risk factors for neonatal hypothyroidism among women with Graves' disease treated with antithyroid drugs until delivery

A Yoshihara , JY Noh , K Inoue , N Watanabe , M Fukushita , M Matsumoto , N Suzuki , A Suzuki , A Kinoshita , R Yoshimura , A Aida , H Imai , S Hiruma , K Sugino , K Ito

Brief summary: Neonates of mothers suffering from Graves’ Disease during pregnancy are at risk for hyper- or hypothyroidism postnatally. The risk for hypothyroidism of neonates exposed to maternal anti-thyroid drugs until birth is unknown. This large retrospective study aimed at investigating 1) the incidence of hypothyroid neonates in a large cohort of mothers treated with anti-thyroid drugs until birth, and 2) identify a cutoff for maternal anti-thyroid drug doses assoc...

ey0020.1-5 | Follow-up Paper from the 2022 Yearbook | ESPEYB20

1.5. Evaluation of the molecular landscape of pediatric thyroid nodules and use of a multigene genomic classifier in children

JN Gallant , SC Chen , CA Ortega , SL Rohde , RH Belcher , JL Netterville , N Baregamian , H Wang , J Liang , F Ye , YE Nikiforov , MN Nikiforova , VL Weiss

Brief summary: In 2021 and 2022, two important publications on pediatric thyroid carcinomas revealed a distinct molecular landscape compared to adult thyroid carcinomas (1,2). Pediatric differentiated thyroid carcinoma was mainly caused by fusion oncogenes, especially in children younger than 10 years (93%), compared to children aged 10–15 years (28%) and 15–20 years old patients (14%). In contrast, PTC due to BRAF mutations showed increasing frequency with age (7%, ...

ey0020.2-3 | Important for Clinical Practice | ESPEYB20

2.3. Timing of puberty, pubertal growth, and adult height in short children born small for gestational age treated with growth hormone

EN Upners , LL Raket , JH Petersen , A Thankamony , E Roche , G Shaikh , J Kirk , H Hoey , SA Ivarsson , O Soder , A Juul , RB Jensen

Brief summary: In this study the authors reported the adult height and timing of puberty of a cohort of Danish children born small for gestational age (SGA) and treated with rhGH in comparison with national growth standards. rhGH treatment significantly increased height SDS in adulthood as compared to the height SDS at treatment start. Age at peak height velocity did not differ compared with the reference cohort, although peak height velocity was reduced in SGA subjects. SGA b...

ey0020.2-15 | New Perspectives | ESPEYB20

2.15. Childhood height growth rate association with the risk of islet autoimmunity and development of type 1 diabetes

Z Li , R Veijola , E Koski , V Anand , F Martin , K Waugh , H Hyoty , C Winkler , MB Killian , M Lundgren , K Ng , M Maziarz , J Toppari

Brief summary: In this study, 10 145 children of 1–8 years of age, selected from a prospective systematic cohort study and stratified according to HLA-risk categories for type-1-diabetes (T1D), underwent a combined evaluation of pancreatic autoimmunity, glucose metabolism and anthropometry at different timeframes. Diagnosis of T1D occurred in 131/10,145 children (1.3%). Faster height growth, both before and after age 3 years, was significantly associated with the appearan...

ey0020.3-7 | Advances in Clinical Practice | ESPEYB20

3.7. Prevalence of monogenic bone disorders in a Dutch cohort of atypical femur fracture patients

W Zhou , JG van Rooij , DM van de Laarschot , Z Zervou , H Bruggenwirth , NM Appelman-Dijkstra , PR Ebeling , S Demirdas , AJ Verkerk , MC Zillikens

In Brief: Prolonged bisphosphonate treatment is associated with atypical femoral fractures (AFF). However, AFFs also occur in bisphosphonate-naïve patients, so bisphosphonate is not a prerequisite for AFF. This study found a higher yield of (likely) pathogenic variants in AFF patients with a clinical suspicion of monogenic bone disorder, stressing the importance of careful clinical evaluation of patients who present with this condition.Commentary: A...